Quantitative and functional alterations of 6-sulfo LacNac dendritic cells in multiple myeloma

References

• Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049–58. doi:10.1182/blood-2014-11-568881. PMID:25838343.
   PubMed Web of Science ®Google Scholar
• Roussou M, Tasidou A, Dimopoulos MA, Kastritis E, Migkou M, Christoulas D, Gavriatopoulou M, Zagouri F, Matsouka C, Anagnostou D, et al. Increased expression of macrophage inflammatory protein-1alpha on trephine biopsies correlates with extensive bone disease, increased angiogenesis and advanced stage in newly diagnosed patients with multiple myeloma. Leukemia. 2009;23:2177–81. doi:10.1038/leu.2009.130. PMID:19587705.
   PubMed Web of Science ®Google Scholar
• Chen H, Campbell RA, Chang Y, Li M, Wang CS, Li J, Sanchez E, Share M, Steinberg J, Berenson A, et al. Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: a novel mechanism of tumor-induced vasculogenesis. Blood. 2009;113:1992–2002. doi:10.1182/blood-2008-02-133751. PMID:19060246.
   PubMed Web of Science ®Google Scholar
• Sponaas AM, Moen SH, Liabakk NB, Feyzi E, Holien T, Kvam S, Grøseth LA, Størdal B, Buene G, Espevik T, et al. The proportion of CD16(+)CD14(dim) monocytes increases with tumor cell load in bone marrow of patients with multiple myeloma. Immun Inflamm Dis. 2015;3:94–102. doi:10.1002/iid3.53. PMID:26029369.
   PubMed Web of Science ®Google Scholar
• Ziegler-Heitbrock L, Ancuta P, Crowe S, Dalod M, Grau V, Hart DN, Leenen PJ, Liu YJ, MacPherson G, Randolph GJ, et al. Nomenclature of monocytes and dendritic cells in blood. Blood. 2010;116:e74–80. doi:10.1182/blood-2010-02-258558. PMID:20628149.
   PubMed Web of Science ®Google Scholar
• Petitprez V, Royer B, Desoutter J, Guiheneuf E, Rigolle A, Marolleau JP, Kamel S, Guillaume N. CD14+ CD16+ monocytes rather than CD14+ CD51/61+ monocytes are a potential cytological marker of circulating osteoclast precursors in multiple myeloma. A preliminary study. Int J Lab Hematol. 2015;37:29–35. doi:10.1111/ijlh.12216.
   PubMed Web of Science ®Google Scholar
• Leone P, Berardi S, Frassanito MA, Ria R, De Re V, Cicco S, Battaglia S, Ditonno P, Dammacco F, Vacca A, et al. Dendritic cells accumulate in the bone marrow of myeloma patients where they protect tumor plasma cells from CD8+ T-cell killing. Blood. 2015;126:1443–51. doi:10.1182/blood-2015-01-623975. PMID:26185130.
   PubMed Web of Science ®Google Scholar
• Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, et al. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309–23. doi:10.1016/j.ccr.2009.08.019. PMID:19800576.
   PubMed Web of Science ®Google Scholar
• Schakel K, Mayer E, Federle C, Schmitz M, Riethmuller G, Rieber EP. A novel dendritic cell population in human blood: one-step immunomagnetic isolation by a specific mAb (M-DC8) and in vitro priming of cytotoxic T lymphocytes. Eur J Immunol. 1998;28:4084–93. doi:10.1002/(SICI)1521-4141(199812)28:12%3c4084::AID-IMMU4084%3e3.0.CO;2-4. PMID:9862344.
   PubMed Web of Science ®Google Scholar
• Hansel A, Gunther C, Ingwersen J, Starke J, Schmitz M, Bachmann M, Meurer M, Rieber EP, Schäkel K. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1T-cell responses. J Allergy Clin Immunol. 2011;127:787–94 e1-9. doi:10.1016/j.jaci.2010.12.009. PMID:21377044.
   PubMed Web of Science ®Google Scholar
• Schakel K, von Kietzell M, Hansel A, Ebling A, Schulze L, Haase M, Semmler C, Sarfati M, Barclay AN, Randolph GJ, et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes. Immunity. 2006;24:767–77. doi:10.1016/j.immuni.2006.03.020. PMID:16782032.
   PubMed Web of Science ®Google Scholar
• Schakel K, Kannagi R, Kniep B, Goto Y, Mitsuoka C, Zwirner J, Soruri A, von Kietzell M, Rieber E. 6-Sulfo LacNAc, a novel carbohydrate modification of PSGL-1, defines an inflammatory type of human dendritic cells. Immunity. 2002;17:289–301. doi:10.1016/S1074-7613(02)00393-X. PMID:12354382.
   PubMed Web of Science ®Google Scholar
• Toma M, Wehner R, Kloss A, Hubner L, Fodelianaki G, Erdmann K, Füssel S, Zastrow S, Meinhardt M, Seliger B, et al. Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis. Oncoimmunology. 2015;4:e1008342. doi:10.1080/2162402X.2015.1008342. PMID:26155414.
   PubMed Web of Science ®Google Scholar
• Vermi W, Micheletti A, Lonardi S, Costantini C, Calzetti F, Nascimbeni R, Bugatti M, Codazzi M, Pinter PC, Schäkel K, et al. slanDCs selectively accumulate in carcinoma-draining lymph nodes and marginate metastatic cells. Nat Commun. 2014;5:3029. doi:10.1038/ncomms4029. PMID:24398631.
   PubMed Web of Science ®Google Scholar
• Micheletti A, Finotti G, Calzetti F, Lonardi S, Zoratti E, Bugatti M, Stefini S, Vermi W, Cassatella MA. slan/M-DC8+ cells constitute a distinct subset of dendritic cells in human tonsils. Oncotarget. 2016;7:161–75. PMID:26695549.
   PubMedGoogle Scholar
• Rankin SM. Chemokines and adult bone marrow stem cells. Immunol Lett. 2012;145:47–54. doi:10.1016/j.imlet.2012.04.009. PMID:22698183.
   PubMed Web of Science ®Google Scholar
• Zhan F, Hardin J, Kordsmeier B, Bumm K, Zheng M, Tian E, Sanderson R, Yang Y, Wilson C, Zangari M, et al. Global gene expression profiling of multiple myeloma, monoclonal gammopathy of undetermined significance, and normal bone marrow plasma cells. Blood. 2002;99:1745–57. doi:10.1182/blood.V99.5.1745. PMID:11861292.
   PubMed Web of Science ®Google Scholar
• Beider K, Bitner H, Leiba M, Gutwein O, Koren-Michowitz M, Ostrovsky O, Abraham M, Wald H, Galun E, Peled A, et al. Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype. Oncotarget. 2014;5:11283–96. doi:10.18632/oncotarget.2207. PMID:25526031.
   PubMedGoogle Scholar
• Brown RD, Pope B, Murray A, Esdale W, Sze DM, Gibson J, Ho PJ, Hart D, Joshua D. Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10. Blood. 2001;98:2992–8. doi:10.1182/blood.V98.10.2992. PMID:11698282.
   PubMed Web of Science ®Google Scholar
• Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, et al. Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences. Blood. 1999;93:1487–95. PMID:10029575.
   PubMed Web of Science ®Google Scholar
• Ratta M, Fagnoni F, Curti A, Vescovini R, Sansoni P, Oliviero B, Fogli M, Ferri E, Della Cuna GR, Tura S, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood. 2002;100:230–7. doi:10.1182/blood.V100.1.230. PMID:12070032.
   PubMed Web of Science ®Google Scholar
• Ma Y, Aymeric L, Locher C, Kroemer G, Zitvogel L. The dendritic cell-tumor cross-talk in cancer. Curr Opin Immunol. 2011;23:146–52. doi:10.1016/j.coi.2010.09.008. PMID:20970973.
   PubMed Web of Science ®Google Scholar
• Wehner R, Lobel B, Bornhauser M, Schakel K, Cartellieri M, Bachmann M, Rieber EP, Schmitz M. Reciprocal activating interaction between 6-sulfo LacNAc+ dendritic cells and NK cells. Int J Cancer. 2009;124:358–66. doi:10.1002/ijc.23962. PMID:18942710.
   PubMed Web of Science ®Google Scholar
• Langosch S, Wehner R, Malecka A, Franks HA, Schakel K, Bachmann M, Jackson AM, Schmitz M. Impact of p38 mitogen-activated protein kinase inhibition on immunostimulatory properties of human 6-sulfo LacNAc dendritic cells. Immunobiology. 2016;221:166–74. doi:10.1016/j.imbio.2015.09.012. PMID:26391152.
   PubMed Web of Science ®Google Scholar
• Ancuta P. A slan-based nomenclature for monocytes? Blood. 2015;126:2536–8. doi:10.1182/blood-2015-10-675470. PMID:26635407.
   PubMed Web of Science ®Google Scholar
• Arana P, Zabaleta A, Lasa M, Maiso P, Alignani D, Jelinek T, Segura V, van den Bossche W, Teodosio C, Damasceno D, et al. High-Throughput Characterization and New Insight into the Role of Tumor Associated Macrophages (TAMs) in Multiple Myeloma (MM). Blood. 2016;128:482.
   Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, Oomen LA, Peipp M, Valerius T, Slootstra JW, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840–8. doi:10.4049/jimmunol.1003032. PMID:21187443.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Jansen JH, Nederend M, Lammerts van Bueren JJ, Groen RW, Parren PW, Leusen JH, Boross P, et al. The Therapeutic CD38 Monoclonal Antibody Daratumumab Induces Programmed Cell Death via Fcgamma Receptor-Mediated Cross-Linking. J Immunol. 2016;197:807–13. doi:10.4049/jimmunol.1501351. PMID:27316683.
   PubMed Web of Science ®Google Scholar
• Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311–21. doi:10.1080/19420862.2015.1007813. PMID:25760767.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, Kumar S, Hillengass J, Kastritis E, Richardson P, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538–48. doi:10.1016/S1470-2045(14)70442-5. PMID:25439696.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, et al. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011;117:4691–5. doi:10.1182/blood-2010-10-299487. PMID:21292775.
   PubMed Web of Science ®Google Scholar